Another novel approach evaluated CD5-targeted CAR-T cells in 19 heavily pretreated R/R T-ALL patients, many of whom had relapsed after prior CD7 CAR-T therapy [59]. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.